Company: BNBX
Filing Date: 2025-12-30
Form Type: 424B3
Source: 0001104659-25-125037
Chunk: 23

Company: BNB PLUS CORP.
Filing Date: 2025-12-30
Form: 424B3
Chunk 23
---
 where we have established
laboratories for the manufacture and development of our nucleic acid production solutions. The mailing address of our corporate headquarters
is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

Available Information

Because we are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we file or furnish, as applicable, annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. We make available on our website at www.bnb.plus
and www.adnas.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. The information in or accessible through the websites referred to above is not incorporated into, and
is not considered part of, this prospectus. Further, our references to the URLs for these websites are intended to be inactive textual
references only.

Implications of Being a Smaller Reporting Company

We are a “smaller reporting
company,” as defined in the Exchange Act, and have elected to take advantage of certain of the scaled disclosures available to
smaller reporting companies. We will continue to be a “smaller reporting company” until we have $250 million or more in public
float (based on our Common Stock) measured as of the last business day of our most recently completed second fiscal quarter or, in the
event we have no public float (based on our Common Stock) or a public float (based on our Common Stock) that is less than $700 million,
annual revenues of $100 million or more during the most recently completed fiscal year.

We may choose to take advantage
of some, but not all, of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly,
the information contained herein may be different from the information you receive from other public companies in which you hold stock.

<div align='center'>11

Summary of the Offering</div>

| Shares                                      
 offered by the Selling Stockholders         |     | 18,728,341                                                                                                                                  
 Shares held by the Selling Stockholders.                                                                                                    |
| Common                                      
 Stock outstanding prior to this offering    |     |